These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 26678311

  • 1. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
    Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, Micucci G, Giantomassi F, Mozzicafreddo G, Alterini R, Filosa G, Ricotti G, Simonacci M, Scortechini AR, Zizzi A, Pimpinelli N.
    Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
    Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A.
    Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M.
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [Abstract] [Full Text] [Related]

  • 4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 5. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK, Lebwohl M.
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [Abstract] [Full Text] [Related]

  • 6. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, Kulikowski W, Prejzner W, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Rogowski W, Grzanka A, Placek W, Lugowska-Umer H, Kowalczyk A, Nowicki R, Jurczak W.
    Am J Ther; 2016 Sep; 23(3):e749-56. PubMed ID: 24732904
    [Abstract] [Full Text] [Related]

  • 7. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M.
    J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
    [Abstract] [Full Text] [Related]

  • 8. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
    Talpur R, Thompson A, Gangar P, Duvic M.
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
    [Abstract] [Full Text] [Related]

  • 9. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
    Huang J, Cowper S, Moss J, Girardi M.
    J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
    [Abstract] [Full Text] [Related]

  • 10. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M, García-Arpa M, González-García J.
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of mycosis fungoides with PUVA and bexarotene].
    Ortiz-Romero PL, Sánchez-Largo ME, Sanz H, García-Romero D, Rosales B, Valverde R, Arrue I, Polo I, Ruiz D, Fernández-Herrera J, Vanaclocha F.
    Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
    [Abstract] [Full Text] [Related]

  • 12. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R, Duvic M.
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [Abstract] [Full Text] [Related]

  • 13. Phototherapy for mycosis fungoides.
    Dogra S, Mahajan R.
    Indian J Dermatol Venereol Leprol; 2015 May; 81(2):124-35. PubMed ID: 25751327
    [Abstract] [Full Text] [Related]

  • 14. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F, Lebwohl MG.
    J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
    [Abstract] [Full Text] [Related]

  • 15. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
    D'Acunto C, Gurioli C, Neri I.
    J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
    [Abstract] [Full Text] [Related]

  • 16. Long-term control of mycosis fungoides of the hands with topical bexarotene.
    Lain T, Talpur R, Duvic M.
    Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
    [Abstract] [Full Text] [Related]

  • 17. Follicular mycosis fungoides: successful treatment with oral bexarotene.
    Shistik G, Scalf LA, Fenske N, Glass LF.
    J Drugs Dermatol; 2004 Mar; 3(3):301-4. PubMed ID: 15176165
    [Abstract] [Full Text] [Related]

  • 18. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group.
    Rupoli S, Barulli S, Guiducci B, Offidani M, Mozzicafreddo G, Simonacci M, Filosa G, Giacchetti A, Ricotti G, Brandozzi G, Cataldi I, Serresi S, Ceschini R, Bugatti L, Offidani A, Giangiacomi M, Brancorsini D, Leoni P.
    Haematologica; 1999 Sep; 84(9):809-13. PubMed ID: 10477454
    [Abstract] [Full Text] [Related]

  • 19. [Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA].
    Wirtz M, Helbig D.
    Hautarzt; 2014 Apr; 65(4):274-6. PubMed ID: 24671704
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.
    Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Paul-Gunther S, Hofer A, Gruber-Wackernagel A, Legat F, Patra V, Quehenberger F, Cerroni L, Clark R, Wolf P.
    JAMA Dermatol; 2019 May 01; 155(5):538-547. PubMed ID: 30892603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.